skip to Main Content

Dr. O’Reilly on the Potential Role of Veliparib in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Eileen O’Reilly, MD, Winthrop Rockefeller Endowed Chair in Medical Oncology; co-director of Medical Initiatives at the David M. Rubenstein Center for Pancreatic Cancer Research; section head of Hepatopancreaticobilary and Neuroendocrine Cancers; and medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the potential role of veliparib in pancreatic cancer.

Veliparib is a PARP inhibitor that is not yet approved by the FDA for use in any setting, says O’Reilly. A phase II trial presented at the 2020 Gastrointestinal Cancers Symposium examined the addition of veliparib to cisplatin and gemcitabine in treatment-naïve patients with stage III or IV pancreatic cancer with a germline BRCA1/2 or PALB2 mutation. Although a benefit was not observed with the addition of veliparib to combination chemotherapy, a very encouraging survival signal was reported, says O’Reilly. Watch here . . .

Back To Top